140 related articles for article (PubMed ID: 36552031)
1. Development and Characterization of Phage-Display-Derived Novel Human Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2.
Kim JW; Min SW; Lee J; Shin HG; Choi HL; Yang HR; Lee JH; Cho YB; Shim H; Lee S
Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36552031
[TBL] [Abstract][Full Text] [Related]
2. A novel bispecific antibody dual-targeting approach for enhanced neutralization against fast-evolving SARS-CoV-2 variants.
Kim JW; Kim HJ; Heo K; Lee Y; Jang HJ; Lee HY; Park JW; Cho YB; Lee JH; Shin HG; Yang HR; Choi HL; Shim HB; Lee S
Front Immunol; 2023; 14():1271508. PubMed ID: 37822941
[TBL] [Abstract][Full Text] [Related]
3. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
4. Single-domain antibodies against SARS-CoV-2 RBD from a two-stage phage screening of universal and focused synthetic libraries.
Chen F; Liu Z; Kang W; Jiang F; Yang X; Yin F; Zhou Z; Li Z
BMC Infect Dis; 2024 Feb; 24(1):199. PubMed ID: 38350843
[TBL] [Abstract][Full Text] [Related]
5. Development and Characterization of Phage Display-Derived Monoclonal Antibodies to the S2 Domain of Spike Proteins of Wild-Type SARS-CoV-2 and Multiple Variants.
Kim JW; Cho AH; Shin HG; Jang SH; Cho SY; Lee YR; Lee S
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680213
[TBL] [Abstract][Full Text] [Related]
6. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
[TBL] [Abstract][Full Text] [Related]
7. Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy.
Zeng X; Li L; Lin J; Li X; Liu B; Kong Y; Zeng S; Du J; Xiao H; Zhang T; Zhang S; Liu J
Antib Ther; 2020 Apr; 3(2):95-100. PubMed ID: 33912790
[TBL] [Abstract][Full Text] [Related]
8. Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain.
Gao X; Fan L; Zheng B; Li H; Wang J; Zhang L; Li J; Zhu F
Hum Vaccin Immunother; 2022 Nov; 18(5):2055373. PubMed ID: 35417303
[TBL] [Abstract][Full Text] [Related]
9. Potent neutralizing RBD-specific antibody cocktail against SARS-CoV-2 and its mutant.
Jia L; Liu YP; Tian LF; Xiong C; Xu X; Qu H; Xiong W; Zhou D; Wang F; Liu Z; Yan XX; Xu W; Tang L
MedComm (2020); 2021 Sep; 2(3):442-452. PubMed ID: 34541573
[TBL] [Abstract][Full Text] [Related]
10. A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations.
Bertoglio F; Fühner V; Ruschig M; Heine PA; Abassi L; Klünemann T; Rand U; Meier D; Langreder N; Steinke S; Ballmann R; Schneider KT; Roth KDR; Kuhn P; Riese P; Schäckermann D; Korn J; Koch A; Chaudhry MZ; Eschke K; Kim Y; Zock-Emmenthal S; Becker M; Scholz M; Moreira GMSG; Wenzel EV; Russo G; Garritsen HSP; Casu S; Gerstner A; Roth G; Adler J; Trimpert J; Hermann A; Schirrmann T; Dübel S; Frenzel A; Van den Heuvel J; Čičin-Šain L; Schubert M; Hust M
Cell Rep; 2021 Jul; 36(4):109433. PubMed ID: 34273271
[TBL] [Abstract][Full Text] [Related]
11. Generation and utility of a single-chain fragment variable monoclonal antibody platform against a baculovirus expressed recombinant receptor binding domain of SARS-CoV-2 spike protein.
Salem R; El-Kholy AA; Waly FR; Ayman D; Sakr A; Hussein M
Mol Immunol; 2022 Jan; 141():287-296. PubMed ID: 34915268
[TBL] [Abstract][Full Text] [Related]
12. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA
J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections.
Lai R; Zhou T; Xiang X; Lu J; Xin H; Xie Q
Front Med; 2021 Aug; 15(4):644-648. PubMed ID: 33909259
[TBL] [Abstract][Full Text] [Related]
14. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus.
van den Brink EN; Ter Meulen J; Cox F; Jongeneelen MA; Thijsse A; Throsby M; Marissen WE; Rood PM; Bakker AB; Gelderblom HR; Martina BE; Osterhaus AD; Preiser W; Doerr HW; de Kruif J; Goudsmit J
J Virol; 2005 Feb; 79(3):1635-44. PubMed ID: 15650189
[TBL] [Abstract][Full Text] [Related]
15. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
[TBL] [Abstract][Full Text] [Related]
16. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM
mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754
[TBL] [Abstract][Full Text] [Related]
18. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
[TBL] [Abstract][Full Text] [Related]
19. Human neutralizing antibodies elicited by SARS-CoV-2 infection.
Ju B; Zhang Q; Ge J; Wang R; Sun J; Ge X; Yu J; Shan S; Zhou B; Song S; Tang X; Yu J; Lan J; Yuan J; Wang H; Zhao J; Zhang S; Wang Y; Shi X; Liu L; Zhao J; Wang X; Zhang Z; Zhang L
Nature; 2020 Aug; 584(7819):115-119. PubMed ID: 32454513
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern.
Valdovino-Navarro BJ; Dueñas S; Flores-Acosta GI; Gasperin-Bulbarela J; Bernaldez-Sarabia J; Cabanillas-Bernal O; Cervantes-Luevano KE; Licea-Navarro AF
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
